Aduro BioTech Inc (NASDAQ:ADRO) has analysts on the Bullish side this week.

August 30, 2017 - By reb123z

 Aduro BioTech Inc (NASDAQ:ADRO) has analysts on the Bullish side this week.

Aduro BioTech Inc (NASDAQ:ADRO) Ratings Coverage

Among 9 analysts covering Aduro Biotech (NASDAQ:ADRO), 6 have Buy rating, 1 Sell and 2 Hold. Therefore 67% are positive. Aduro Biotech had 13 analyst reports since August 19, 2015 according to SRatingsIntel. H.C. Wainwright maintained the shares of ADRO in report on Thursday, August 3 with “Buy” rating. The stock of Aduro BioTech Inc (NASDAQ:ADRO) has “Perform” rating given on Tuesday, December 1 by Oppenheimer. Oppenheimer initiated Aduro BioTech Inc (NASDAQ:ADRO) rating on Tuesday, October 20. Oppenheimer has “Outperform” rating and $30 target. The rating was maintained by Roth Capital with “Buy” on Tuesday, November 24. The firm has “Buy” rating by Cowen & Co given on Tuesday, July 18. The firm has “Underperform” rating given on Tuesday, March 15 by Bank of America. The rating was initiated by Leerink Swann on Wednesday, August 19 with “”. Roth Capital maintained the shares of ADRO in report on Thursday, August 27 with “Buy” rating. The rating was maintained by FBR Capital with “Outperform” on Tuesday, May 17. The rating was maintained by TH Capital on Tuesday, November 24 with “Buy”. Below is a list of Aduro BioTech Inc (NASDAQ:ADRO) latest ratings and price target changes.

03/08/2017 Broker: Canaccord Genuity Rating: Buy New Target: $30.0000
03/08/2017 Broker: H.C. Wainwright Rating: Buy New Target: $18.0000 Maintain
18/07/2017 Broker: Cowen & Co Rating: Buy Initiate
07/03/2017 Broker: Roth Capital Rating: Buy New Target: $17.00 Maintain

It closed at $11.25 lastly. It is down 1.22% since August 30, 2016 and is uptrending. It has underperformed by 15.48% the S&P500.

Aduro Biotech, Inc. is an immunotherapy company, which focuses on the discovery, development and commercialization of therapies that manage the treatment of various diseases, including cancer. The company has market cap of $828.86 million. The Company’s product candidates from its Live, Attenuated, Double-Deleted Listeria monocytogenes, Stimulator of Interferon Genes Pathway Activator, and B-select monoclonal antibody platforms are designed to stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies, as well as other immunotherapies. It currently has negative earnings. The Company’s LADD technology platform is being developed as a treatment for multiple indications, including mesothelioma, ovarian, gastric, lung and prostate cancers.

More notable recent Aduro BioTech Inc (NASDAQ:ADRO) news were published by: Globenewswire.com which released: “Aduro Biotech Announces Andrea van Elsas, Ph.D., to be Named Chief Scientific …” on July 27, 2017, also Globenewswire.com with their article: “Aduro Biotech Announces Management Promotions” published on April 20, 2017, Globenewswire.com published: “Aduro Biotech Reports First Quarter 2017 Financial Results” on May 02, 2017. More interesting news about Aduro BioTech Inc (NASDAQ:ADRO) were released by: Globenewswire.com and their article: “Aduro Biotech Bolsters Intellectual Property Position in STING Field with Two …” published on August 09, 2017 as well as Seekingalpha.com‘s news article titled: “Aduro Biotech: Buy, Sell Or Hold?” with publication date: August 26, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.